| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC0766 | At7519m | Novel inhibitor of cyclin-dependent kinases 1, 2, 4, 5, and 9 with in vitro activity against lymphoid malignancies |
|
| DCC0767 | Atag2139 | Novel degrader of MTH1 fusion proteins for use within the aTAG system |
|
| DCC0768 | aTAG 4531 Featured | aTAG 4531 (CFT-4531) is a potent, selective, and onmechanism tool degrader of MTH1 with DC50 value of 0.28 nM and Ki value of 1.8 nM. degradation activity is due to the intricate formation of the ternary complex between the MTH1 aTAG, CRBN E3 ligase, and aTAG tool degrader . |
|
| DCC0769 | Atb-345 | Hydrogen sulfide-releasing cyclooxygenase inhibitor |
|
| DCC0770 | Atcaa-1 | Potent cytotoxic agent for both prostate cancer and melanoma |
|
| DCC0771 | Atd-3169 | Novel ROS generator, permeating mycobacteria to reliably enhance endogenous ROS including superoxide radical |
|
| DCC0772 | Atenolol Hydrochloride | Selective ß1 receptor antagonist |
|
| DCC0773 | Atiprimod Dimaleate | Potent JAK2 inhibitor |
|
| DCC0774 | Atl802 | Novel selective A2BR antagonist |
|
| DCC0775 | Atm-1001 | Novel inhibitor of the cancer-associated tropomyosin 3.1 (Tpm3.1), suppressing glucose-stimulated insulin secretion (GSIS) from the pancreatic islets |
|
| DCC0776 | a-tocopheryl 2,3,5-triiodobenzoate | Novel non-toxic contrast agent for micro-CT imaging |
|
| DCC0777 | Atp-alpha-ch2-gamma-thio | Novel potent inhibitor of nucleotide pyrophosphatase/phosphodiesterase-1 (NPP1) |
|
| DCC0778 | atqthb | Novel antitimor agent, exhibiting superior anti-proliferative activity, excellent chemo-sensitizing activity against pancreatic cancer in vitro and in combination with Gemcitabine |
|
| DCC0779 | Atromentin | Natural potent apoptosis inducer in U937 cells, inducing caspase-3 processing, PARP, and DNA fragmentation |
|
| DCC0780 | Atsp-3900 | Novel Potent Dual Inhibitor of MDM2 and MDMX (Ki =1 nM) |
|
| DCC0781 | Atsp-7041 | Novel potent and selective dual inhibitor of MDM2 (Ki = 0.9 nM) and MDMX (Ki = 7 nM) |
|
| DCC0782 | Atuveciclib | Novel potent, highly selective, orally bioavailable CDK9/P-TEFb inhibitor |
|
| DCC0783 | Atx-1905 | Novel Potent Autotaxin (ATX) Ligand |
|
| DCC0784 | Atx-in-31 | Novel selective Autotaxin (ATX) inhibitor |
|
| DCC0785 | Auh-6-96 | Novel inhibitor of JAK/STAT signaling, inhibiting both constitutive and interleukin-6-induced STAT3 phosphorylation, selectively affecting cell viability only of cancer cells harboring aberrant JAK/STAT signaling |
|
| DCC0786 | aureusidin | Potent inhibitor of HCV RdR |
|
| DCC0787 | Aurka-in-12 | Novel AURKA inhibitor, reducing clonogenicity, arresting the cell cycle at the G2/M phase, and inducing caspase-mediated apoptotic cell death in HCT116 human colon cancer cells |
|
| DCC0788 | Auromomycin | Natural antibiotic |
|
| DCC0789 | Aurone-4-3 | Novel inhibitor of AChE, suppressing Aβ aggregation, protecting Caenorhabditis elegans against Aβ- and 6-OHDA-induced neurotoxicities dose-dependently |
|
| DCC0790 | Aurone-51 | Potent inhibitor of HCV RdR |
|
| DCC0791 | Aurora A Inhibitor-9 | Novel small 4 integrin antagonist, preventing the development of experimental colitis in mice. |
|
| DCC0792 | Aurora-in-1 | Novel potent ATP-competitive inhibitor of Aurora A/B/C (5.6/18.4/24.6 nM) |
|
| DCC0793 | Austrocortirubin | Novel DNA damage inducer during G0/G1, S, and G2 cell cycle phases via a mechanism unique from other DNA damaging agents |
|
| DCC0794 | Authipyrin | Novel autophagy inhibitor, targeting mitochondrial complex I directly, leading to the potent inhibition of mitochondrial respiration as well as autophagy |
|
| DCC0795 | Autoinducer-2 | Unique signaling molecule used in quorum sensing |
|
